Category Archives: News

Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer

Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer Framingham, MA – October 20, 2021.  Kephera Diagnostics has been awarded a $1,999,961 million Phase II Small Business Innovative Research (SBIR) contract by the National Cancer Institute, an agency of…

NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease

NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease National Institutes of Health awards contract to develop a test-of-cure for Chagas disease Framingham, MA – September 23, 2021.  The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH),…

Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination

Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination Framingham, MA – July 13, 2021 – Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through…

Kephera Diagnostics receives $417,074 grant award from the Massachusetts Life Sciences Center to accelerate development of its rapid COVID-19 Antigen Test

Kephera Diagnostics receives $417,074 grant award from the Massachusetts Life Sciences Center to accelerate development of its rapid COVID-19 Antigen Test Baker-Polito Administration and Massachusetts Life Sciences Center Announce More Than $1.5 Million to Support Development and Acceleration of Coronavirus Testing Solutions The full text of this announcement can be viewed at https://www.mass.gov/news/baker-polito-administration-and-massachusetts-life-sciences-center-announce-more-than-15 BOSTON —…

Kephera Diagnostics’ new CLIA laboratory launches testing for COVID-19 antibodies

Kephera Diagnostics’ new CLIA laboratory launches testing for COVID-19 antibodies Framingham, MA – August 5, 2020 – Kephera Diagnostics announced today that it has been approved as a CLIA certified laboratory by the Massachusetts Dept of Public Health and the U.S. Centers for Medicare and Medicaid, and is now offering COVID-19 antibody testing in Massachusetts…

Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test

Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test Framingham, MA – July 23, 2020. Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases…

Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test.

Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test. Framingham, MA, April 24, 2020…….Kephera Diagnostics has launched a new study aimed at collecting blood samples from  volunteers at least 18 years of age who have been confirmed positive for COVID-19, for use…

NIAID awards grant to Kephera Diagnostics for point-of-care test for Neurocysticercosis

NIAID awards grant to Kephera Diagnostics for point-of-care test for Neurocysticercosis Framingham, MA – January 13, 2020.  Kephera Diagnostics has been awarded a two-year, $600,000 Phase I SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a point-of-care test for Neurocysticercosis, the company announced today.  Neurocysticercosis is an infection of…

Kephera Diagnostics awarded contract from the National Cancer Institute for development of a test for parasite linked to a rare cancer

Kephera Diagnostics awarded contract from the National Cancer Institute for development of a test for parasite linked to a rare cancer The National Cancer Institute, an agency of the National Institutes of Health, has awarded a Phase I Small Business Innovative Research (SBIR) contract to Kephera Diagnostics (Framingham, MA) for $299,997 to develop a test for liver…

National Institutes of Health awards grant for novel test-of-cure for Chagas disease

National Institutes of Health awards grant for novel test-of-cure for Chagas disease Framingham, MA – July 16, 2019.  The National Institute of Allergy and Infectious Diseases, an agency of the National Institutes of Health (NIH), has awarded a two-year, $594,008 Small Business Innovative Research (SBIR) grant to Kephera Diagnostics to develop a test-of-cure for Chagas…